New Treatment Options for Oncology Indications
- March 2, 2018
In 2017, the brisk pace of drug approvals from the US Food and Drug Administration allowed an influx of new treatment options for oncology indications. These included novel breakthrough treatments for solid tumors and hematologic malignancies, new and expanded indications for existing approved therapies, and the addition of new agents in drug classes with already demonstrated success. As the rapid evolution of the oncology treatment landscape is expected to continue, it is important for oncology care providers and decision-makers to stay informed about the latest generation of treatment options as well as their impact on standard of care. To review all of the 2017 FDA Approvals of Oncology Products by Indication, click here.